APA (7th ed.) Citation

Kim, D., & Thomas, M. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): Updated results from the multicentre, open-label, phase 1 trial. The lancet. Oncology, 17(4), . https://doi.org/10.1016/S1470-2045(15)00614-2

Chicago Style (17th ed.) Citation

Kim, Dong-Wan, and Michael Thomas. "Activity and Safety of Ceritinib in Patients with ALK-rearranged Non-small-cell Lung Cancer (ASCEND-1): Updated Results from the Multicentre, Open-label, Phase 1 Trial." The Lancet. Oncology 17, no. 4 (2016). https://doi.org/10.1016/S1470-2045(15)00614-2.

MLA (9th ed.) Citation

Kim, Dong-Wan, and Michael Thomas. "Activity and Safety of Ceritinib in Patients with ALK-rearranged Non-small-cell Lung Cancer (ASCEND-1): Updated Results from the Multicentre, Open-label, Phase 1 Trial." The Lancet. Oncology, vol. 17, no. 4, 2016, https://doi.org/10.1016/S1470-2045(15)00614-2.